Keloid Tissue Bank

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Much progress in treatment of various tumors has been made in the laboratory and the results have been brought back to the patients, i.e. from bench to bedside. This trial intends to collect samples of keloid tissue from patients and study them in laboratory. Such a research may help us with finding better treatments for keloid.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To aims of this trial are:

1. To prospectively collect keloid and normal skin tissue samples from patients with keloid by performing keloid tissue biopsy and biopsy of uninvolved skin.
2. To collect blood and/or saliva for genomics, proteomics, tissue culture, flow cytometery and other keloid investigational studies.
3. To collect any keloid tissue that has been previously removed from the patient (unrelated to enrollment on this study).
4. To prospectively collect keloid tissue from patients who are undergoing a planned surgical removal of their keloids.
5. To evaluate keloid histology, genomics, proteomics, molecular markers, cytokines, growth factors receptors, ligands and signal transduction pathways within keloid tissue in order to find druggable targets.
6. To prospectively follow the patients and correlate patient demographics and natural history of the disease, response to the past and future treatments with the genomic and molecular maker profiles.
7. To culture nucleated blood cells from keloid patients in order to determine the genomics of this disease as well as learning about potential presence of keloid stem cell in peripheral blood. To use flow cytometry as well as other technology to search for circulating keloid stem cells in peripheral blood.
8. To test in vitro:

A- The effect of small molecule kinase inhibitors on the activation of wild-type and mutant kinases.

B- The effects of various drugs that inhibit ligands, receptors or pathways.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keloid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with keloid

All patients will have a clinical diagnosis of keloid and will consent to participate in this study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must have clinically confirmed diagnosis of keloid
2. Signed consent form; parent or a legal guardian should consent for children and those under age of 18.
3. Have at least one paraffin block of excess keloid tissue that has been removed in the past; or is planned to be removed in future.
4. Able and willing to undergo a keloid biopsy (optional)
5. Able and willing to undergo biopsy of their normal appearing skin (optional, minimum age 18).

Exclusion Criteria

1. Individuals who are mentally challenged, who cannot consent to participate in this study.
2. Psychological Illness that may result in non-compliance with the procedure and the required follow up.
3. Known allergy to lidocaine or other local anesthetics.

Minimum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael H Tirgan, MD

Role: STUDY_CHAIR

Keloid Research Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michael H. Tirgan, MD

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Tirgan 11-02

Identifier Type: -

Identifier Source: org_study_id